









Markets
/
Stocks
/
nasdaq-mrna
/

Moderna Inc

MRNA

53.530USD

+2.250+4.39%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

17.37BMarket Cap

LossP/E TTM



Moderna Inc

53.530

+2.250+4.39%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Moderna Inc

Currency: USD Updated: 2026-03-24

Key Insights

Moderna Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 62 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 43.36.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Moderna Inc's Score

Industry at a Glance

Industry Ranking

62 / 157

Overall Ranking

174 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

1°C



Very Low

Very High

Neutral

Moderna Inc Highlights

StrengthsRisks

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Fairly Valued

The company’s latest PE is -7.08, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 297.93M shares, decreasing 5.64% quarter-over-quarter.

Held by Scotia Canadian Dividend Fund

Star Investor Scotia Canadian Dividend Fund holds 64.35K shares of this stock.

Analyst Rating

Based on 25 analysts

Hold

Current Rating

43.355

Target Price

-15.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-24

The current financial score of Moderna Inc is 8.21, ranking 65 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 678.00M, representing a year-over-year decrease of 29.81%, while its net profit experienced a year-over-year decrease of 26.25%.

Score

Industry at a Glance

Previous score

8.21

Change



Financials

7.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.09

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.69

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Moderna Inc's Company Valuation

Currency: USD Updated: 2026-03-24

The current valuation score of Moderna Inc is 7.60, ranking 57 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -7.08, which is -667.08% below the recent high of 40.13 and -62.67% above the recent low of -11.51.

Score

Industry at a Glance

Previous score

7.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 62/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-24

The current earnings forecast score of Moderna Inc is 5.92, ranking 140 out of 157 in the Pharmaceuticals industry. The average price target is 28.00, with a high of 135.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

5.92

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 25 analysts

Hold

Current Rating

43.355

Target Price

-15.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Moderna Inc

MRNA

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-24

The current price momentum score of Moderna Inc is 6.69, ranking 77 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 57.90 and the support level at 46.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.72

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-1.259

Neutral

RSI(14)

57.061

Neutral

STOCH(KDJ)(9,3,3)

35.396

Buy

ATR(14)

3.042

Low Volatility

CCI(14)

16.464

Neutral

Williams %R

50.115

Neutral

TRIX(12,20)

0.433

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

51.982

Buy

MA10

52.550

Buy

MA20

53.215

Buy

MA50

48.144

Buy

MA100

38.158

Buy

MA200

32.850

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-24

The current institutional shareholding score of Moderna Inc is 7.00, ranking 42 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 76.26%, representing a quarter-over-quarter increase of 2.76%. The largest institutional shareholder is The Vanguard, holding a total of 41.50M shares, representing 10.51% of shares outstanding, with 0.93% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

41.10M

-1.24%

Fidelity Management & Research Company LLC

12.28M

-36.87%

BlackRock Institutional Trust Company, N.A.

20.00M

+1.82%

Baillie Gifford & Co.

Star Investors

21.85M

-1.12%

State Street Investment Management (US)

17.11M

-0.94%

Two Sigma Investments, LP

14.30M

-3.19%

Geode Capital Management, L.L.C.

9.25M

+4.19%

Boston Biotech Ventures, L.L.C.

9.21M

Theleme Partners LLP

8.07M

+2.54%

Risk Assessment

Currency: USD Updated: 2026-03-24

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Moderna Inc is 5.44, ranking 66 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.33. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Moderna Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.